Peter J. Krause

TL;DR: These updated guidelines replace the previous treatment guidelines published in 2000 and list the doses and durations of antimicrobial therapy recommended for treatment and prevention of Lyme disease and provide a partial list of therapies to be avoided.

TL;DR: This quality standard is designed to provide an implementation mechanism that will facilitate the reliable administration of prophylactic antimicrobial agents to patients undergoing operative procedures in which such a practice is judged to be beneficial and to provide a guideline that will help local hospital committees formulate policies and set up mechanisms for their implementation.

TL;DR: The possibility of concomitant babesial infection should be considered when moderate to severe Lyme disease has been diagnosed and the number of symptoms and duration of illness in patients with concurrent Lyme disease and babesiosis are greater than in Patients with either infection alone.

TL;DR: Disease may occur throughout the world because of the widespread prevalence of this pathogen in ixodid ticks.

TL;DR: For the treatment of babesiosis, a regimen of atovaquone and azithromycin is as effective as a program of clindamycin and quinine and is associated with fewer adverse reactions.